Role of Topical Phytotherapy on the Risk Factor of Elevated Level of Serum Aldolase-A in Knee-Osteoarthritis: Part II. A Systematic Meta-Analysis
Background: Knee-osteoarthritis (KOA) is a degenerative joint disease. Elevated level of aldolase-A (AldoA) in serum indicates skeletal muscle damage in KOA. The present study was attempted to normalize the elevated level of AldoA by topical phytotherapeutic protocol correlated with leg-anatomy, body mass index (BMI), pain, stiffness and physical function and the Kellgren-Lawrence (KL) grading-systems.
Methods: Baseline data from144 patients (61.80% females) with KOA aged 40-75 years old were recruited in this cross-sectional study. Bilateral anatomy of legs including the gap at the knee between the short head of the biceps femoris and the surface of the bed, diameter of muscles 4cm above and below the patella, angles of straight leg raising, flexion and extension in different positions and BMI were measured using appropriate instruments. AldoA was estimated in serum. The KL grading-system of radiographic KOA and overall pain under VAS and pain, stiffness and physical function under WOMAC index were also evaluated. All the parameters were compared between the baseline and post-42 days of treatment.
Results: The anatomical features were observed symmetry in both legs at the end of the 42nd session with highly statistical significance (P<0.0001). The significant changes were also observed in VAS (P<0.00001), WOMAC index (P<0.001), AldoA level (P<0.0001), BMI (P<0.0001) and improvement of KL grading systems was noted for both knee-joints.
Conclusion: The functional improvements of skeletal muscles confirmed with normalization of elevated AldoA level, leg-anatomical measurements, BMI, VAS, WOMAC index and KL grading systems of radiographic KOA due to the effects of phytochemicals present in phytoextracts.
2. Rehbein-Thoner M, Pffleiderer. The changes in aldolase isoenzyme pattern during development of the human kidney and small intestine- demonstrated in organ extracts of tissue structure. Physiol Chem. 1977;358 G:169-180.
3. Kellgren JH, Lawrence JS. Rheumatismin miners.II.X-ray study. Br J IndMed. 1952;197-207.
4. Sugiyama M, Hong Z, Liang P-H, Dean SM, Whalen LJ, Greenberg WA,et al. D-fructose-6-phosphate Aldolase-catalyzed one-pot synthesis of iminocyclitols. J Am Chem Soc. 2007;129:14811-14817.
5. Garnero P, Piperno M, Gineyts E, Christgau S, DelmasPD,Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis. 2001;60:619-626.
6. Liu J, Shikhman AR, Lotz MK, Wong C-H. Hexosaminidase inhibitors as new drug candidates for the therapy of osteoarthritis. Chemistry and Biology 2001;8(7):701-711.
7. Parsons S, Alesci S, Feuerstein G,Wang J. Biomarkers in the development of novel disease-modifying therapies for osteoarthritis. Biomarkers Med. 2008;2(6):587-602.
8. .DamEB, LoogM,Christiansen C, Byrjalsen I, Folkesson J, Nielsen M, et al. Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers. Arthritis Res Ther. 2009; 11(4):R115, doi: 10.1186/ar2774.
9. Razzaque I. Aldolase reference range. 2014; 11 December http://emedicine.medscape. com/article/ 2087158-overview.
10. Jacob W, Neuhaus J. Die Aktivität der SerumAldolasebei der progressivenMuskeldystrophie (ERB). KlinWochenschr. 1954;32(37-38):923-924.
11. Sibley JE, Fleisher GA. The clinical significance of serum Aldolase. Proc Staff Meet Mayo Clin.1954;29(23):591-603.
12. Thomson WHS, Leyburn P, Walton JN. Serum enzyme activity in muscular dystrophy. Br Med J. 1960;2(5208):1276-1281.
13. Long F, Cal X, Luo W, Chen L, Li K. Role of Aldolase in osteosarcoma progression and metastasis: In vitro and in vivo evidence. Oncol Rep. 2014;32(5):2031-2037.
14. GangulyA.Topicalphytotherapeutic treatment for obtaining knee symmetry in osteoarthritis – a sustainable approach. International Journal of Phytomedicine. 2015a;6:489-509.
15. Ganguly A. Diagnosis, Prevention &Phytotherapy for Osteoarthritic Disorders, (ISBN: 978-3-330-65274-3), Scholars Press Book 2017a; pp:13,14,46-48.
16. Ganguly A. Normalization of varus/ valgus deformities in osteoarthritis by external application of phytoconstituents : Confirmed with anatomical observations and biochemical profiles and radiological images.Ant Physiol. 6:224.doi:10.4172/2161-0940:1000224.
17. Ganguly A, Bandopadhyay S, Banerjee S K, Hatai B, Hatai J. Impact of superoxide dismutase (SOD) and glutathione reductase (GR) activity as markers of oxidative-stree and their role in inflammation with osteoarthritis patients. European Journal of Pharmaceutical and Medical Research. 2017,4(2):495-500.
18. Haslam E. Natural polyphenols (vegetable tannins) as drugs: possible modes of action. J Nat Prod. 1996;59:205-215.
19. Chantia A. Traditional Knowledge of ethno medicine in Jaunsarbawar, Dehradun district. Indian J Tradit Know. 2003;2(4):397-399.
20. Kurian JC. Ethno-medicinal plants of India, Thailand and Vietnam. J Biodiversity. 2012; 3(1):61-75.
21. Singh GB, Atal CK. Pharmacology of an extract of salaiguggal ex-Boswelliaserrata, a new non-steroidal anti-inflammatory agent. Agents Actions.1986;18:407-412.
22. Lalithakumari K, Krishnaraju AV, Sengupta K, Subbaraju GV, Chatterjee A. Safety and toxicological evaluation of a novel, standardized 3-O-acetyl-11-keto-β-boswellic acid (AKBA)-enriched Boswelliaserrataextract (5-Loxin). Toxicol Mechanisms Methods. 2006; 16:199-226.
23. Sengupta K, Alluri KV, Satish AR, Mishra S, Golakoti T, Sarma KVS, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin® for treatment of osteoarthritis of the knee. Arthritis Res Therp. 2008;10(4):R85, doi:10.1186/ar2461.
24. Schumacher HR, Pullman-Mooar S, Gupta SR, Dinnella JE, Kim R,McHugh MP. Randomized double-blind crossover study of the efficacy of a tart cherry juice blend in treatment of osteoarthritis (OA) of the knee. Osteoarthritis and Cartilage 2013;21(8):1035-1041.
25. Wang Q, Pan X, Wong HH, Wagner CA, Lahey LJ, Robinson WH, et al. Oral and topical boswellic acid attenuates mouse osteoarthritis. Osteoarthr. Cartil. 2014;22(1):128-132.
26. Belcaro G,Ganguly A,Dugall M, Luzzi R, Hosoi M, Ledda A, Feragalli B, et al. PHYTOPROFLEX: supplementary management of osteoarthritis: a pilot, open, supplement registry. MedinovaMedica 2017 (in press).
27. Ganguly A. Degenerative changes in lumbar-region occur simultaneously with bilateral-osteoarthritic changes in knee-joints and vice versa: Normalization with topical application of phytoconstiuents by specialized techniques involving possible cartilage-regeneration. International Journal of Recent Scientific Research 2015c;6(9):6331-6346.
28. Ganguly A. Obtaining normal flexion and extension of knee joints on supine, prone and standing positions in osteoarthritis by topical phytotherapeutic treatment irrespective of age and sex. International Journal of Phytomedicine. 2015d;7(3):290-301
29. Ganguly A. Degenerative changes in lumbar region always lead to bilateral degenerative changes in knee-joints and vice-versa: Sensation of pain cannot only be the parameter of degeneration. AnatPhysol. 2015b;S4-005, doi:10/41722161-0940.S4-005.
30. Ganguly A. Diagnosis of knee osteoarthritis risk through abnormal musculo-postural features. .International Archives of Biomedical and Clinical Research 2018 (in press).
31. American Academy of Orthopedic Surgeons (AAOS), Joint motion: method of measuring and recording, E. & S. Livingstone Ltd. Edinburgh, 1965, 4th reprint 1969.
32. Feissli S. Quantitative determination of Aldolase. Klin. Wschr. 1966;44:390.
33. Scott J, Huskisson EC. Graphic representation of pain. Pain.1976;2:175-184.
34. Haefeli M, Elfering A. Pain assessment. Eur Spine J. 2006;15:S17-S24.
35. Bellamy N, Buchnan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol.1988;15:1833-1840.
36. Ganguly A. Efficacy of phytotherapeutic protocol for the risk factor of elevated level of serum c-reactive protein in knee-osteoarthritis: Part I. A systematic meta-analysis. International Archives of Biomedical and Clinical Research 2018 (in press).
37. Gonçalves FB, Rocha FA, Albuquerque RP, Mozella A de P, Crespo B, Cobra H. Reproducibility assessment of different descriptions of the Kellgren and Lawrence classification for osteoarthritis of the knee. RevistaBrasileira de Ortopedia. 2016;51(6):687-691.